NasdaqGS:KRYSBiotechs
Krystal Biotech (KRYS) After The KB801 Update And Why Valuation Still Splits Opinion
KB801 disclosure and why it matters for Krystal Biotech stock
Krystal Biotech (KRYS) recently filed a response with the U.S. Patent and Trademark Office related to its KB801 gene therapy for neurotrophic keratitis, sharing new single patient data from a discontinued clinical study.
The company reported complete closure of a persistent corneal epithelial defect in that patient, with no serious safety concerns observed in the study. It also stressed that the observation does not represent trial...